Procrit (Epoetin Alfa-EPBX, Biosimilar to Epogen) 20,000 Units/mL

– Reduction of need for red blood cell (RBC) transfusion in patients with chronic kidney disease (CKD) on dialysis and not on dialysis

– Initiate treatment when hemoglobin (Hgb) level <10 g/dL

– If Hgb level approaches or >11 g/dL, reduce or interrupt dose

– 50-100 units/kg IV/SC 3 times weekly initially

– Initiating treatment only when Hbg level is <10 g/dL and the following:

– Rate of Hgb decline indicates the likelihood of requiring a RBC transfusion

– Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal

– If Hgb level >10 g/dL, reduce or interrupt dose, and use the lowest dose of epoetin alfa sufficient to reduce the need for RBC transfusions

– 50-100 units/kg IV 3 times weekly initially

– Treatment of anemia in patients with non-myeloid malignancies where anemia is due to effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy

– Initial Dose: 150 units/kg IV/SC 3 times weekly

– 40,000 units SC once weekly until completion of chemotherapy course